FOXO1 and Hepatic fibrosis: Therapeutically targeting this pathway with inhibitors that block FoxO1 phosphorylation or restore its function may effectively reduce liver fibrosis by diminishing HSC activation, enhancing apoptosis, and alleviating inflammation.